Ocuphire Pharma News

Ocuphire Pharma | 424B3: Prospectus

Feb 16 16:33 ET

Ocuphire Pharma | EFFECT: Others

Jan 24 06:04 ET

Ocuphire Pharma | 424B5: Prospectus

Aug 14, 2023 08:00 ET

Ocuphire Pharma | 424B5: Prospectus

Jun 7, 2021 16:21 ET

Ocuphire Pharma | 424B5: Prospectus

Mar 11, 2021 09:19 ET

Ocuphire Pharma | 424B4: Prospectus

Feb 17, 2021 07:14 ET

Ocuphire Pharma | EFFECT: Others

Feb 16, 2021 00:19 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Nov 3, 2020 06:04 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Oct 20, 2020 08:55 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Oct 16, 2020 16:01 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Oct 9, 2020 16:01 ET

Ocuphire Pharma | EFFECT: Others

Oct 5, 2020 00:21 ET

Ocuphire Pharma | 424B3: Prospectus

Oct 2, 2020 09:25 ET

Ocuphire Pharma | S-4/A: Registration of securities issued in business combination transactions (Amendment)

Sep 30, 2020 09:17 ET

Ocuphire Pharma | S-4/A: Registration of securities issued in business combination transactions (Amendment)

Sep 15, 2020 21:50 ET

Ocuphire Pharma | S-4/A: Registration of securities issued in business combination transactions (Amendment)

Aug 27, 2020 17:04 ET

Ocuphire Pharma | S-4: Registration of securities issued in business combination transactions

Jul 6, 2020 16:08 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Jul 1, 2020 08:35 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Jun 19, 2020 09:00 ET

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Jun 18, 2020 09:14 ET